A Randomized, Open, Multi-center, Phase III Study of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients
Phase of Trial: Phase III
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Cisplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 04 Jun 2019 Safety and efficacy results (n=558) presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 18 Jan 2019 Status changed from recruiting to completed.
- 20 Jul 2018 Planned End Date changed from 1 Mar 2018 to 1 Sep 2018.